Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.
Ian M CatlettLu GaoYanhua HuSubhashis BanerjeeJames G KruegerPublished in: Dermatology and therapy (2024)
NCT02931838.